Castle Biosciences, Inc.

NASDAQ:CSTL

31.8 (USD) • At close November 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 85.78287.00272.97466.1261.49350.13842.03738.33837.01134.83826.85225.03923.47522.75822.81317.29915.21712.71517.41817.63514.77510.7398.71711.4363.7123.9793.659
Cost of Revenue 15.60917.2316.57915.09411.31911.05810.1829.528.8597.6865.9444.5974.53.6973.0282.6732.4752.1462.3912.0111.7091.9931.5981.3661.3511.3271.253
Gross Profit 70.17369.77256.39551.02650.17439.0831.85528.81828.15227.15220.90820.44218.97519.06119.78514.62612.74210.56915.02715.62413.0668.7467.11910.072.3612.6532.406
Gross Profit Ratio 0.8180.8020.7730.7720.8160.7790.7580.7520.7610.7790.7790.8160.8080.8380.8670.8450.8370.8310.8630.8860.8840.8140.8170.8810.6360.6670.658
Reseach & Development Expenses 12.32314.05113.45512.9112.92313.30814.39311.30910.90711.92610.7619.4457.56.7935.9084.5813.0582.7042.9133.1591.5151.3171.3941.1381.2941.1591.263
General & Administrative Expenses 018.41317.95117.12616.12316.42916.81730.15514.23815.9170000014.95911.70310.39211.0789.8527.1226.8216.04703.9184.164.228
Selling & Marketing Expenses 032.67530.54426.96428.49628.25229.945-43.96922.38821.581000000000-00000000
SG&A 50.49950.70948.41143.77444.61944.68146.76238.42636.62637.49830.45325.1622.59520.82218.16114.95911.70310.39211.0789.8527.1226.8216.0474.1643.9184.164.228
Other Expenses 2.2722.2472.2472.2712.2722.2482.2222.2152.3062.0974.215.6050.6940.25600000-0-2.71-0.19-0.033-0.243-0.0430.034-0.021
Operating Expenses 65.09464.7661.86656.68459.81460.23763.37751.9549.83951.52145.42435.61330.78927.87124.06917.65816.64311.21413.99113.0118.6378.1387.445.3025.2135.3195.49
Operating Income 5.0795.012-5.471-5.658-9.64-21.157-31.522-23.132-21.687-24.369-24.516-15.171-11.814-8.81-4.284-3.032-3.901-0.6451.0362.6134.4290.608-0.3214.767-2.852-2.666-3.085
Operating Income Ratio 0.0590.058-0.075-0.086-0.157-0.422-0.75-0.603-0.586-0.699-0.913-0.606-0.503-0.387-0.188-0.175-0.256-0.0510.0590.1480.30.057-0.0370.417-0.768-0.67-0.843
Total Other Income Expenses Net 3.2032.8742.9823.1172.7672.3962.3322.2711.28720.7640.0270.0160.0230.0240.004-1.773-0.688-0.731-0.466-0.4861.42-1.877-1.036-0.89-0.598-0.489-0.546
Income Before Tax 8.2827.886-2.489-2.541-6.873-18.761-29.19-20.561-20.249-3.605-24.489-15.155-11.791-8.786-4.28-4.805-4.589-1.3760.572.1275.849-1.269-1.3583.877-3.45-3.155-3.63
Income Before Tax Ratio 0.0970.091-0.034-0.038-0.112-0.374-0.694-0.536-0.547-0.103-0.912-0.605-0.502-0.386-0.188-0.278-0.302-0.1080.0330.1210.396-0.118-0.1560.339-0.929-0.793-0.992
Income Tax Expense 6.013-1.0340.0450.0390.0320.0160.0140.057-1.438-1.9570.134-8.7250.0230.0050.0040.0840.0180.0380.2980.072306.469995.6670.9910.0090.5260.5590.51
Net Income 2.2698.92-2.534-2.58-6.905-18.777-29.204-20.618-18.811-1.648-24.623-6.43-11.791-8.791-4.28-4.889-4.589-1.3760.572.0555.849-1.269-1.3583.868-3.45-3.155-3.63
Net Income Ratio 0.0260.103-0.035-0.039-0.112-0.375-0.695-0.538-0.508-0.047-0.917-0.257-0.502-0.386-0.188-0.283-0.302-0.1080.0330.1170.396-0.118-0.1560.338-0.929-0.793-0.992
EPS 0.0820.32-0.092-0.095-0.26-0.7-1.1-0.78-0.72-0.063-0.97-0.25-0.47-0.35-0.17-0.24-0.23-0.080.030.120.43-0.082-0.130.36-0.32-0.3-0.34
EPS Diluted 0.0770.31-0.092-0.095-0.26-0.7-1.1-0.78-0.71-0.063-0.97-0.25-0.47-0.35-0.17-0.23-0.23-0.0780.030.110.05-0.082-0.130.36-0.32-0.3-0.34
EBITDA 12.02411.5040.8650.685-3.697-15.718-26.294-17.716-17.32-0.973-22.335-13.704-10.702-8.152-4.047-4.25-3.764-0.5051.4252.9937.0280.511-0.2544.607-2.798-2.55-3.02
EBITDA Ratio 0.140.096-0.029-0.037-0.06-0.313-0.625-0.486-0.472-0.613-0.832-0.565-0.456-0.358-0.177-0.174-0.247-0.040.0820.1640.1230.039-0.0290.403-0.754-0.641-0.826